<DOC>
	<DOCNO>NCT01701674</DOCNO>
	<brief_summary>Purpose Pilot Study : The investigator want study safety , side effect , benefit TILs give drug ipilimumab . Ipilimumab type immunotherapy - drug use boost ability immune system fight cancer , infection , disease .</brief_summary>
	<brief_title>Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer High Dose IL-2 Melanoma Mets Pts</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must unresectable metastatic stage IV melanoma stage III intransit regional nodal disease , opinion institutional PI acceptable candidate ACT high dose IL2 Residual measurable disease resection target lesion ( ) TIL growth Tumor may BRAF V600 mutation BRAF wild type , patient must previously treat ipilimumab Clinical performance status Eastern Cooperative Oncology Group ( ECOG ) 0 1 . ECOG performance status 01 infer patient 's level energy ≥ 50 % baseline . May previously treat metastatic disease , may prior systemic treatment . Patients V600 BRAF mutate tumor may previously receive prior BRAF inhibitor . Women childbearing potential ( WOCBP ) must negative serum pregnancy test within 7 day screen . Adequate renal , hepatic hematologic function , include creatinine less equal 1.7 gm/dL , total bilirubin less equal 2.0 mg/dL , except patient Gilbert 's Syndrome must total bilirubin less 3.0 mg/dL , aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) less 3 X institutional upper limit normal , hemoglobin 8 gm/dL , white blood count ( WBC ) 3000 per mcL total granulocyte 1000 per mcL , platelets 100,000 per mcL . Must positive screening EpsteinBarr virus ( EBV ) antibody titre screen test Patients antibiotic allergy per se exclude ; although production TIL adoptive transfer include antibiotic , extensive wash harvest minimize systemic exposure antibiotic . At screening , patient ≤ 3 untreated CNS metastasis may include provide none untreated lesion &gt; 1 cm great dimension , peritumoral edema present brain imaging ( MRI CT MRI contraindicate ) . At screening , patient central nervous system ( CNS ) metastases treat either surgical resection and/or radiation therapy may include . Patients may include large lesion ≤ 1 cm , evidence progressive CNS disease brain image least 28 day treatment . At screening , patient may include large lesion &gt; 1 cm &gt; 3 number , evidence progressive CNS disease brain image least 90 day treatment surgery and/or radiation therapy . No evidence ongoing cardiac dysrhythmia ≥ grade 2 ( NCI Common Terminology Criteria Adverse Events [ CTCAE ] , v4.0 ) All laboratory image study must complete satisfactory within 30 day sign consent document , exception : negative serum pregnancy test woman childbearing potential must negative within 7 day screen , human leukocyte antigen ( HLA ) type repeat perform previously , pulmonary function test ( PFTs ) /cardiac stress test whose result valid 6 month perform previously . Patients active systemic infection require intravenous antibiotic , coagulation disorder major medical illness cardiovascular , respiratory immune system , opinion principal investigator ( PI ) treat coinvestigator acceptable risk ACT , exclude . Patients test positive HIV titre , Hepatitis B surface antigen , Hepatitis B core antibody , Hepatitis C antibody , Human TLymphotropic Virus ( HTLV ) I II antibody , Rapid . Plasma Reagin ( RPR ) fluorescent treponemal antibody ( FTA ) positive exclude . Pregnant nursing Patients need chronic , immunosuppressive systemic steroid exclude History autoimmune disease require immunosuppressive medication time screen Presence significant psychiatric disease , opinion principal investigator designee , would prevent adequate inform consent render immunotherapy unsafe contraindicate Patients &gt; 3 untreated CNS metastases evidence peritumoral edema Patients ≤ 3 untreated CNS metastasis least one lesion &gt; 1 cm peritumoral edema Patients invasive malignancy melanoma time enrollment within 2 year prior first TIL administration exclude , except adequately treat ( curative intent ) basal squamous cell carcinoma , situ carcinoma cervix , situ ductal adenocarcinoma breast , situ prostate cancer , limited stage bladder cancer cancer patient diseasefree least 2 year . Patients treat CNS metastasis &gt; 1 cm &gt; 3 number exclude evidence progressive CNS disease brain image least 90 day treatment surgery and/or radiation therapy . Unable comprehend give inform consent Male patient WOCBP partner agree use two FDAaccepted form contraception sexual intercourse woman childbearing potential start ipilimumab least 6 month ACT WOCBP agree use 2 FDA form contraception sexual intercourse start ipilimumab least 6 month ACT Patients receive ipilimumab past</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>skin cancer</keyword>
</DOC>